Subscribe
Israel-Hamas Conflict
Election Day
NBA
Donald Trump
US Economy
Kamala Harris
US Politics
McDonald's
Republican Party
US Presidential Election
Barack Obama
Halloween
US Crime
Published

Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names - Novo Nordisk (NYSE:NVO), Eli Lilly (NYSE:LLY)

Summary by Benzinga
Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) have dominated the obesity drug market with their leading therapies, Wegovy and Zepbound, but the next generation of treatments could shift this dynamic. These new drugs, expected to hit the market by 2029, aim to surpass current efficacy levels while offering more convenient dosing options, such as oral and monthly injections. This shift, driven by innovation and competition, could cha…
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Eli LillyEli Lilly
WegovyWegovy

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

Trending Topics
Ground News logo
App Store IconPlay Store Icon
CompanyAboutHistoryMissionBlogTestimonialsGroup SubscriptionsSubscribeGiftFree TrialCareersAffiliates
HelpHelp CenterFAQContact UsFor Educators/LibrariesMedia Bias RatingsOwnership and Factuality RatingsReferral CodeNews SourcesTopics
ToolsAppBrowser ExtensionDaily NewsletterBlindspot Report NewsletterBurst Your Bubble NewsletterTimelines
DonatePrivacy PolicyManage CookiesTerms and Conditions
© 2024 Snapwise Inc
News
For You
Search
BlindspotLocal